Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00764738 · ClinicalTrials.gov registry record · Phase 2
Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
A Phase 2 study of Neovascular Age-related Macular Degeneration, sponsored by Retina Macula Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
- 1
- Study location
NCT00764738: Completed Phase 2 study of Neovascular Age-related Macular Degeneration, sponsored by Retina Macula Institute.
NCT00764738 is a Phase 2 study of Neovascular Age-related Macular Degeneration that has completed, run by Retina Macula Institute. The registered enrollment target is 91 participants, below the 406-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00764738, a Phase 2 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Retina Macula Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
Visual outcomes using monthly ranibizumab therapy are well established in clinical trials, but the best way to assess when and how to treat patients with PRN therapy has not been proven. Information is lacking on Multi-focal ERG and microperimetry outcomes with ranibizumab therapy. Additionally, VA and OCT outcomes don't always correlate and other assessments such as the Multi-focal ERG and microperimetry may be useful as early predictors of when patients should be retreated. This study will assess 2 groups (monthly and PRN therapy) and assess high resolution OCT, microperimetry, and Multi-focal ERG outcomes. For the PRN group retreatment will be based on OCT criteria. We will investigate if microperimetry or multifocal ERG would have been an early predictor of fluid recurrence.
Conditions Studied
Interventions
- DEVICE OCT, Multifocal ERG, Microperimetry
- DRUG Ranibizumab Ophthalmic
Study Locations (1)
California
- Retina Macula Institute - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00764738
The ClinicalTrials.gov registry entry for NCT00764738 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 406-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (78% lower). The listed sponsor is Retina Macula Institute, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which OCT, Multifocal ERG, Microperimetry is the first listed.
NCT00764738 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00764738 about?
NCT00764738 is a clinical study titled "Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration". Visual outcomes using monthly ranibizumab therapy are well established in clinical trials, but the best way to assess when and how to treat patients with PRN therapy has not been proven. Information is lacking on Multi-focal ERG and microperimetry outcomes with ranibizumab therapy. Additionally, VA ...
What is the current status of trial NCT00764738?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2008-10. Estimated completion is 2011-11.
What conditions does trial NCT00764738 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT00764738?
The interventions under investigation include: OCT, Multifocal ERG, Microperimetry (DEVICE), Ranibizumab Ophthalmic (DRUG).
Who is sponsoring clinical trial NCT00764738?
This trial is sponsored by Retina Macula Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00764738 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
COMPLETED · Phase 2
-
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
COMPLETED · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.